Schrödinger: An Interesting Investment With Immense Potential
Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...
Karolinska Development AB: Year-end Report - January-December 2024
Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. "Stronger ...
Pharm Exec17h
Q&A: Gain Therapeutics CEO Discuss AI-Driven Drug Discovery, Strategic Growth Plans
Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...
manilatimes22h
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company's FDA discussions confirmed that relapse-free survival ...
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) Philadelphia, Pennsylvania--(Newsfile ...